AIM IMMUNOTECH INC (AIM)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$0.23-2.61%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AIM
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue clinical development of Ampligen with completed Phase 2 enrollment and dosing, planning Phase 3 trial with key data expected in 2027.
Newly stated in 2026-Q2. Management reported completion of enrollment and dosing in the metastatic pancreatic cancer Phase 2 trial and plans for a pivotal Phase 3 study with key clinical data expected in Q1 and Q3 2027. Ampligen showed a median Overall Survival of 34.8 months compared to 12.5 months historical controls in a related program. This priority is newly emphasized with clinical milestones forthcoming.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Completed enrollment and Ampligen dosing in metastatic pancreatic cancer Phase 2 trial, positioning for Phase 3 development.”
Ensure ongoing compliance with NYSE American listing requirements, including stockholders' equity minimums.
Newly stated in 2026-Q2. Management announced regaining compliance with NYSE American listing standards by resolving stockholders' equity deficiency, achieving equity above the $6.0 million minimum. This priority is delivering as the company is no longer noncompliant.
“Successfully regained full compliance with NYSE American's continued listing standards.”
Raise capital via registered direct offerings and private placements to fund clinical trials and working capital.
Newly stated in 2026-Q2. Management completed equity offerings raising approximately $2.65 million to fund clinical drug supply, clinical trials, and working capital. This capital raising activity is delivering as planned in the quarter.
“Entered definitive agreements for registered direct offering and private placement raising approx. $2.65 million.”
Seek non-dilutive government funding to evaluate Ampligen's antiviral potential against Ebola virus disease.
Newly stated in 2026-Q2. Management disclosed plans to pursue government-funded initiatives for Ampligen's antiviral potential against Ebola virus disease as part of a non-dilutive funding strategy. This is a recent strategic focus with no financial metrics yet available.
“Planning government-focused initiatives to evaluate Ampligen's antiviral potential against Ebola virus disease.”
Focus on manufacturing clinical drug supply and conducting Phase 3 clinical trials for Ampligen.
Over the trailing year it converted 0.78x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, the US dollar, long-term interest rates (low R² over the window).
37 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.